Raymond James Financial Inc. Reduces Stock Position in Qiagen N.V. $QGEN

Key Points

• Raymond James Financial Inc. reduced its stake in Qiagen N.V. by 10.5% in Q1, holding 222,314 shares valued at approximately $8.93 million.
• Over 70% of Qiagen's stock is owned by institutional investors, with several funds, including Wealth Enhancement Advisory Services LLC and GAMMA Investing LLC, recently changing their positions.
• Qiagen reported a quarterly revenue increase of 7.7%, reaching $533.54 million, meeting analysts' expectations for earnings per share at $0.60.

Raymond James Financial Inc. cut its holdings in shares of Qiagen N.V. (NYSE:QGEN - Free Report) by 10.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 222,314 shares of the company's stock after selling 26,000 shares during the quarter. Raymond James Financial Inc. owned 0.10% of Qiagen worth $8,926,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in QGEN. ANTIPODES PARTNERS Ltd bought a new position in shares of Qiagen during the first quarter worth approximately $94,000. Tower Research Capital LLC TRC increased its stake in Qiagen by 770.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock valued at $111,000 after acquiring an additional 2,204 shares during the last quarter. GAMMA Investing LLC increased its stake in Qiagen by 93.9% in the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after acquiring an additional 1,425 shares during the last quarter. Federated Hermes Inc. bought a new position in Qiagen in the first quarter valued at approximately $150,000. Finally, Wealth Enhancement Advisory Services LLC bought a new position in Qiagen in the fourth quarter valued at approximately $202,000. 70.00% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on QGEN shares. Barclays assumed coverage on shares of Qiagen in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 price objective on the stock. Bank of America lifted their price target on shares of Qiagen from $50.00 to $53.00 and gave the stock a "buy" rating in a report on Thursday, June 26th. Wall Street Zen lowered shares of Qiagen from a "strong-buy" rating to a "buy" rating in a report on Monday, August 11th. Cowen restated a "hold" rating on shares of Qiagen in a report on Thursday, August 7th. Finally, UBS Group boosted their target price on shares of Qiagen from $48.00 to $50.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. Three research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $49.69.

Qiagen Stock Performance

QGEN traded up $0.18 during midday trading on Thursday, reaching $46.88. The company had a trading volume of 435,288 shares, compared to its average volume of 1,393,184. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61. The stock has a market cap of $10.42 billion, a PE ratio of 27.70, a P/E/G ratio of 2.57 and a beta of 0.64. Qiagen N.V. has a 12-month low of $37.63 and a 12-month high of $51.88. The business has a 50-day moving average price of $48.68 and a two-hundred day moving average price of $44.25.

Qiagen (NYSE:QGEN - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, meeting analysts' consensus estimates of $0.60. The firm had revenue of $533.54 million for the quarter, compared to analysts' expectations of $523.97 million. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The company's quarterly revenue was up 7.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.55 earnings per share. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, sell-side analysts expect that Qiagen N.V. will post 2.26 earnings per share for the current fiscal year.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.